• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults.

作者信息

Kiyoi H, Yamaji S, Kojima S, Naoe T

出版信息

Leukemia. 2007 Mar;21(3):574-6. doi: 10.1038/sj.leu.2404527. Epub 2007 Jan 25.

DOI:10.1038/sj.leu.2404527
PMID:17252020
Abstract
摘要

相似文献

1
JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults.JAK3突变在唐氏综合征儿童和非唐氏综合征成人的急性巨核细胞白血病中均有发生。
Leukemia. 2007 Mar;21(3):574-6. doi: 10.1038/sj.leu.2404527. Epub 2007 Jan 25.
2
Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome.一名无唐氏综合征的婴儿在短暂性骨髓增殖性疾病后发生的无GATA1突变的急性巨核细胞白血病。
J Clin Oncol. 2011 Mar 20;29(9):e230-3. doi: 10.1200/JCO.2010.32.3634. Epub 2011 Jan 4.
3
Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.一名患有临床明显的短暂性骨髓增殖性疾病的唐氏综合征患者，急性巨核细胞白血病由一个微小克隆发展而来。
J Pediatr Hematol Oncol. 2006 Oct;28(10):696-8. doi: 10.1097/01.mph.0000212997.02554.f6.
4
Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome.
Blood. 2004 Jan 1;103(1):366. doi: 10.1182/blood-2003-09-3219.
5
Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome.唐氏综合征相关的短暂性骨髓增殖性疾病和急性巨核细胞白血病中JAK3突变的功能分析
Br J Haematol. 2008 May;141(5):681-8. doi: 10.1111/j.1365-2141.2008.07081.x. Epub 2008 Apr 7.
6
Acute megakaryoblastic leukemia and severe pulmonary fibrosis in a child with Down syndrome: successful treatment with ultra low-dose cytarabine using GATA1 mutation to monitor minimal residual disease.
Am J Hematol. 2012 Apr;87(4):447-50. doi: 10.1002/ajh.23130. Epub 2012 Mar 3.
7
Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.唐氏综合征短暂性骨髓增殖性疾病和急性巨核细胞白血病中GATA1基因的突变
Blood Cells Mol Dis. 2003 Nov-Dec;31(3):351-6. doi: 10.1016/j.bcmd.2003.08.001.
8
GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.唐氏综合征中的GATA1突变：对患有短暂性骨髓增殖性疾病和急性巨核细胞白血病儿童的生物学及诊断的意义
Pediatr Blood Cancer. 2005 Jan;44(1):40-4. doi: 10.1002/pbc.20066.
9
GATA1 mutations in myeloproliferative disorders: nomenclature standardization and review of the literature.
Hum Mutat. 2005 Oct;26(4):390-2. doi: 10.1002/humu.20233.
10
GATA 1 mutations as clonal markers of minimal residual disease in acute megakaryoblastic leukemia of Down syndrome--a new tool with significant potential applications.GATA 1突变作为唐氏综合征急性巨核细胞白血病微小残留病的克隆标志物——一种具有重要潜在应用价值的新工具。
Leuk Res. 2005 Nov;29(11):1239-40. doi: 10.1016/j.leukres.2005.04.019.

引用本文的文献

1
Malignant JAK-signaling: at the interface of inflammation and malignant transformation.恶性JAK信号传导：炎症与恶性转化的交汇点
Leukemia. 2025 May;39(5):1011-1030. doi: 10.1038/s41375-025-02569-8. Epub 2025 Mar 26.
2
Therapeutic advances of targeting receptor tyrosine kinases in cancer.靶向治疗癌症受体酪氨酸激酶的治疗进展。
Signal Transduct Target Ther. 2024 Aug 14;9(1):201. doi: 10.1038/s41392-024-01899-w.
3
Janus Kinase 3 (JAK3): A Critical Conserved Node in Immunity Disrupted in Immune Cell Cancer and Immunodeficiency.
Janus激酶3（JAK3）：免疫中的关键保守节点，在免疫细胞癌症和免疫缺陷中被破坏。
Int J Mol Sci. 2024 Mar 4;25(5):2977. doi: 10.3390/ijms25052977.
4
Zebrafish Model of Severe Combined Immunodeficiency (SCID) Due to JAK3 Mutation.斑马鱼 JAK3 基因突变所致严重联合免疫缺陷（SCID）模型。
Biomolecules. 2022 Oct 20;12(10):1521. doi: 10.3390/biom12101521.
5
JAK: Not Just Another Kinase.JAK：不只是另一种激酶。
Mol Cancer Ther. 2022 Dec 2;21(12):1757-1764. doi: 10.1158/1535-7163.MCT-22-0323.
6
Advances in molecular characterization of myeloid proliferations associated with Down syndrome.与唐氏综合征相关的髓系增殖性疾病分子特征研究进展
Front Genet. 2022 Aug 10;13:891214. doi: 10.3389/fgene.2022.891214. eCollection 2022.
7
In vivo impact of JAK3 A573V mutation revealed using zebrafish.利用斑马鱼揭示 JAK3 A573V 突变的体内影响。
Cell Mol Life Sci. 2022 May 27;79(6):322. doi: 10.1007/s00018-022-04361-8.
8
The JAK/STAT signaling pathway: from bench to clinic.JAK/STAT 信号通路：从基础到临床。
Signal Transduct Target Ther. 2021 Nov 26;6(1):402. doi: 10.1038/s41392-021-00791-1.
9
The Mutational Landscape of Myeloid Leukaemia in Down Syndrome.唐氏综合征中髓系白血病的突变图谱
Cancers (Basel). 2021 Aug 18;13(16):4144. doi: 10.3390/cancers13164144.
10
Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?解开JAK抑制剂的抗肿瘤和免疫抑制作用——血液系统恶性肿瘤的一种策略？
Cancers (Basel). 2021 May 26;13(11):2611. doi: 10.3390/cancers13112611.